Update on the Latest Developments in Viral and Non-Viral Vector Manufacturing

Guest Editor: Dr Jan Thirkettle, Chief Development Officer, Freeline Therapeutics

 

Building upon the February 2018 Spotlight on Viral and Non-Viral Vector Manufacturing, this series of interviews, articles and webinars will provide an update on the latest developments in optimizing vector and plasmid manufacturing.

Hear from key opinion leaders on the cutting-edge scientific approaches being developed in efforts to refine vector performance, as well as advances in technology platforms to streamline and improve efficiencies in the manufacture of these crucial approaches.

Podcast

Joined-up thinking: success criteria for tomorrow’s viral vector production platforms

Article

Transmission Electron Microscopy: a Critical Component of the Vector Analytical Toolkit

Article

The latest developments in viral and non-viral vector manufacturing

Article

The Growing Promise of Gene Therapy Approaches

Article

Standardizing viral vector manufacture: maximizing production with the TRiP SystemTM

Webinar

Evaluation of Poros AAVX Pan-Affinity Resin for rAAV purification and cGMP Manufacturing

Spotlight

Latest Developments in Viral and Non-Viral Vector Manufacturing – Full Spotlight

Article

Update on the Sleeping Beauty transposon system for therapeutic applications

Webinar

Scalable, helper virus-free AAV production with stable CAP-GT producer cell lines

Article

Joined-up thinking: success criteria for tomorrow’s viral vector production platforms

Podcast

Transmission Electron Microscopy: a Critical Component of the Vector Analytical Toolkit

Article

Keeping viral vector manufacturing in-house: strategic considerations for gene therapy biotechs

Article

Capacity or capability? Getting your priorities right in viral vector manufacturing

Article

Challenges and progress in lentiviral vector bioprocessing

Article

Lentiviral vectors in hematopoietic stem cell therapies: mainstay technology, or simply a bridge to gene editing?

Article

Applying learnings from the bioprocess development of Luxturna™

Article

Scaling up gene therapy manufacturing for multinational pivotal trials & commercialization

Article

AAV meets exosomes: at the cutting edge of cardiovascular gene therapy